MediBeacon Transdermal GFR Measurement System (TGFR)
Medibeacon, Inc. · Decision date Jun 10, 2026
What did the FDA approve?
FDA records P230019/S002 as a supplement to PMA P230019, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jun 10, 2026.
FDA approval order statement
approval for the following labeling revision: (Prior warning statement) Lumitrace injection may interfere with clinical laboratory tests. The presence of Lumitrace decreased B-Type Natriuretic Peptide (BNP) results by around 20% in limited testing. DO NOT ADMINISTER if the patient is expected to need clinical laboratory testing while Lumitrace is present in their system (up to 72 hours for renally impaired patients).(Revised warning statement) Lumitrace injection may interfere with clinical laboratory tests. DO NOT ADMINISTER if the patient is expected to need clinical laboratory testing while Lumitrace is present in their system, which may be for up to 72 hours.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jun 10, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230019/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Medibeacon, Inc.
- Product code
- SDK
- Decision code
- APPR
- Decision date
- Jun 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transdermal test for Assessment of Glomerular Filtration Rate.
- Applicant
- Medibeacon, Inc.
- Product code
- SDK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230019 · Original PMA
MediBeacon Transdermal GFR Measurement System (TGFR)
P230019/S002 received
Application receipt date recorded by FDA.
P230019/S003 · Related supplement
MediBeacon Transdermal GFR Measurement System (GFR)
P230019/S001 · Related supplement
MediBeacon Transdermal GFR Measurement System (TGFR)
P230019/S002 · FDA decision
Real-Time Process
P230019/S005 · Related supplement
MediBeacon Transdermal GFR System
Timeline entries are records held by MedtechLedger for P230019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medibeacon, Inc. | PMA approval | Jan 17, 2025 | FDA | |
| Medibeacon, Inc. | PMA supplement | Nov 20, 2025 | FDA | |
| Medibeacon, Inc. | PMA supplement | Dec 15, 2025 | FDA | |
MediBeacon Transdermal GFR SystemP230019/S005 | Medibeacon, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medibeacon, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 425 N. New Ballas Rd., Suite 100, St. Louis, MO, 63141
Sources and methodology
- Original FDA record: P230019/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


